Alleviation of the severity of SSc could be achieved by intervening in the IFIT3/TBK1 signalling pathway to inhibit the stimulation of pDCs and reduce the liberation of inflammatory factors, as illustrated in Figure 10. This evidence concerns the gene TBK1 and systemic sclerosis.